Clobetasol propionate is under clinical development by AFYX Therapeutics and currently in Phase II for Vulvar Lichen Sclerosus. According to GlobalData, Phase II drugs for Vulvar Lichen Sclerosus does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Clobetasol propionate LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Clobetasol propionate overview
Clobetasol propionate is under development for the treatment of oral lichen planus (OLP), vulvar lichen sclerosus (VLS) and recurrent aphthous stomatitis (RAS). The drug candidate is administered through an oromucosal and topical patch. It is developed based on Rivelin patch technology.
AFYX Therapeutics overview
AFYX Therapeutics is a biopharmaceutical company engaged in research and development of pharmaceuticals aiming for better treatment of diseases including cancer, women’s health and high-scale pain. The company is headquartered in Horsholm, Denmark.
For a complete picture of Clobetasol propionate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
